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ABSTRACT 
INTRODUCTION: Our objective was to compare the levels of three synaptic proteins 
involved in different steps of the synaptic transmission: Rab3A, SNAP25 and neurogranin, in 
three common forms of dementia: Alzheimer’s disease (AD), dementia with Lewy bodies 
(DLB) and Parkinson’s disease dementia (PDD). 
METHODS: 129 post-mortem human brain samples were analyzed in brain regional specific 
manner exploring their associations with morphological changes and cognitive decline. 
RESULTS: We have observed robust changes reflecting synaptic dysfunction in all studied 
dementia groups. There were significant associations between the rate of cognitive decline 
and decreased levels of Rab3 in DLB in the inferior parietal lobe and SNAP25 in AD in the 
prefrontal cortex. Of particular note, synaptic proteins significantly discriminated between 
dementia cases and controls with over 90% sensitivity and specificity.  
DISCUSSION: Our findings suggest that the proposition that synaptic markers can predict 
cognitive decline in AD, should be extended to Lewy body diseases.  
 
Keywords: Dementia with Lewy bodies, Alzheimer’s disease, Parkinson’s disease with 
dementia, Cognitive impairment, Synaptic dysfunction, SNAP25, Rab3A, neurogranin. 
 
Abbreviations: Rab3A- Ras-related protein Rab-3A, SNAP25- synaptosomal-Associated 
Protein, 25kDa, BA9- prefrontal cortex, BA21- temporal lobe neocortex, BA24- anterior 
cingulate cortex, BA40 inferior parietal lobe neocortex  
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1. INTRODUCTION  
The pandemic increase in the number of people with dementia carries serious implications for 
society [1-5].  Whilst there has been a tremendous increase in research and efforts to develop 
new treatments, this has largely focussed on AD. The synuclein dementias, DLB and PDD, 
present with a particularly challenging constellation of symptoms and account for 15% of 
people with dementia, but have received far less attention. As in AD, cholinesterase inhibitors 
provide symptomatic benefits, but efforts to develop disease modifying therapies are at a 
much earlier stage. Previous pathological studies have suggested that the burden of synuclein 
pathology is associated with cognitive decline, and that concurrent AD pathology may also 
contribute [6].  However, this only explains a minority of the variance, and a better 
understanding of disease substrates is needed for targeted drug discovery and to enable better 
monitoring of disease progression. The structural basis of dementia in most 
neurodegenerative disorders is considered to be neuronal and synaptic loss accompanied by 
intraneuronal protein aggregation [7]. Changes in synaptic function are usually reflected by 
alterations in the concentration of synaptic proteins in the pre-synaptic or at the post-synaptic 
density [8]. A significant decrease in cortical synapses has been reported in AD [9, 10]. 
Importantly, initial work suggests that the loss of synapses is more robustly correlated with 
cognitive decline in these individuals than traditional markers of AD pathology [11], 
suggesting that these changes are already evident at the earliest stages of disease [12]. Less is 
known regarding the role of synaptic dysfunction in PDD and DLB [6, 13, 14], but synaptic 
alterations have been demonstrated in Parkinson`s disease [15] and preliminary studies have 
indicated early synaptic changes in DLB/PDD. Consistent with our hypothesis that synaptic 
dysfunction may be particularly important in DLB/PDD, structural imaging studies indicate 
that brain atrophy is less pronounced in DLB and PDD compared to AD [16] despite the 
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more severe disease course [17, 18]. Synaptic dysfunction has been also suggested to be 
caused by presynaptic accumulation of alpha-synuclein aggregates [19]. 
The aim of the current work is therefore to investigate the importance of synaptic changes in 
DLB/PDD and AD, and to provide a more detailed characterization of synaptic changes to 
inform further drug and biomarker discovery. We focused our attention on three synaptic 
proteins that on the grounds of their differential role in the synaptic machinery represent high 
priority candidates for investigation. 
Neurogranin is one of the main postsynaptic proteins involved in the regulation of 
synaptic transmission through its binding to calmodulin at low levels of calcium [20]. 
Synaptosomal associated protein 25 (SNAP25) is known to provide the driving force for 
vesicle fusion and docking [21]. The presynaptic vesicle protein Rab3A, reflects the recycling 
pool of synaptic vesicles [22].  
In the present study we employed an exploratory approach to examine brain regional 
specific distribution of these three synaptic proteins, on prospectively followed, clinically and 
neuropathologically well characterized patients with DLB, PDD, AD and controls without 
dementia. Such information may aid in the development of new diagnostic and prognostic 
biomarkers as well as novel mechanism-based treatments.  
2. MATERIALS AND METHODS: 
2.1 Brain tissue 
Post-mortem human brain tissue (from 129 cases in total) as well as brain sections (17-19 
section/brain region) were provided by the Brains for Dementia Research network including 
cases from the Newcastle Brain Tissue Resource (21 cases), the Thomas Willis Oxford Brain 
Collections (17 cases) and the London Neurodegenerative Diseases Brain Bank (65 cases) as 
well as from the University Hospital Stavanger (26 cases). Autopsy protocols and sample 
collection was harmonized among all the centres. Samples from four different brain regions 
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including prefrontal cortex (BA9), temporal lobe neocortex (BA21), anterior cingulate cortex 
(BA24) and inferior parietal lobe neocortex (BA40) were studied.  
In total, 34 PDD patients (age 68–89 years), 52 DLB patients (age 65–92 years), 18 AD 
patients (age 72–103 years) and 25 aged non-neurological controls (age 65–96 years) were 
included. Not all patients had tissues available for all brain regions and analyses. Assessment 
and diagnostic criteria have been previously described [6].  
Cognitive impairment data was available for the majority of the patients (Supplementary 
Table 1) and consisted of the last Mini-Mental State Examination (MMSE) scores, assessed 
usually within 1- 2 years before death [23] as well as of MMSE decline calculated as the 
decline per year averaged over the period of clinical observation consisting of generally 8–10 
years. All participants gave informed consent for their tissue to be used in research and the 
study was approved by the UK National Research Ethics Service (08/H1010/4), the 
Norwegian committee for medical and health research ethics (2010/633) and by the Regional 
Ethical Review Board in Stockholm (2012/920-31/4). 
2.2 Preparation of tissue samples 
Preparation of tissue for western blotting and ELISA analyses was performed as previously 
described [2]. Briefly, 500 mg of frozen tissue was homogenized in ice-cold buffer 
containing 50 mM Tris-HCL, 5 mM EGTA, 10 mM EDTA, protease inhibitor cocktail tablets 
(Roche, 1 tablet per 50 mL of buffer), and 2 mg/mL pepstatin A dissolved in 
ethanol:dimethyl sulfoxide 2:1 (Sigma). The buffer was used at a ratio of 2mL to every 100 
mg of tissue, and homogenization was performed using an IKA Ultra-Turrax mechanical 
probe (IKA Werke, Germany) until the liquid appeared homogenous. Protein concentration 
of each sample was measured by using BCA Protein Assay Kit (Thermo Scientific). Samples 
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for ELISA measurements were further diluted to 0.1 µg/ µL total protein in phosphate buffer 
saline (PBS) buffer. 
2.3 Sandwich enzyme-linked immunosorbent assays 
We have developed sandwich ELISA for each of the studied synaptic proteins. With the 
exception of the antibodies, the method was identical regardless of the antigen. Details 
regarding antibodies and purified proteins are described in Supplementary Table 2. Detailed 
protocol is described in supplementary methods. Samples of human brain were added in 
dilutions of 0.1 µg/µL of total protein and standards were diluted so that the sample 
absorbance values would fall near 50% binding (the linear range) of the standard curve. The 
coefficient of variation was less than 20% and the accuracy between 80% and 120% for 
acceptance. Concentrations were calculated after the mean blank value had been subtracted. 
2.4 Immunoblotting 
To minimize inter-blot variability, 20 µg total protein/samples were loaded in each lane of 
each gel on 7.5-10% SDS-polyacrylamide gel for protein separation and then transferred to 
nitrocellulose membrane (Immobilon-P, Millipore). Each gel contained a control lane of 
pooled brain homogenates used as an internal standard. After blocking non-specific binding, 
membranes were incubated with primary antibodies followed by HRP conjugated secondary 
antibody. GAPDH was used as a reference protein assessing equal loading. Equal 
concentration of pooled brain homogenate sample was used as an internal control loaded on 
each gel. Bands were visualized using Chemiluminescent substrate (Millipore) in a LAS-
3000 luminescent image reader (Fujifilm). Western blot data were evaluated and quantified 
using Multi Gauge Image Analyzer (version 3.0). 
2.5 Immunohistochemistry 
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Brain tissue was acquired and assessed pathologically as previously described [6]. Formalin 
fixed, wax-embedded blocks, cut into 7µm sections and mounted onto slides, were used for 
immunohistochemistry. Briefly, the sections were dewaxed and rehydrated using Histoclear 
and alcohol dilutions.  Antigen retrieval was carried out by microwaving the sections for ten 
minutes in citrate buffer pH 6.0. Following blocking of endogenous peroxidases (0.3% H2O2 
in PBS for 30 minutes), sections were incubated overnight with antibodies specific for 
neurogranin-1, SNAP25 and Rab3A. Development of the sections was performed using 
biotinylated secondary antibodies, ABC reagents and a DAB kit (all Vector Laboratories, 
Peterborough, UK).  Sections were briefly counterstained with Mayer’s hematoxylin solution 
before dehydration, mounting with DPX and coverslipping.  For control experiments, the 
secondary biotinylated antibody was omitted. 
2.6 Statistical analysis 
For the univariate descriptive analyses, considering the irregular non-Gaussian distribution of 
the samples, nonparametric statistical tests were used. To assess the relationship between 
synaptic proteins neuropathological and MMSE scores, Spearman correlations were 
performed. To compare protein levels between controls and the different patient groups we 
used Kruskal-Wallis tests, followed by Dunn`s post hoc test using the IBM SPSS Statistics 22 
software. In all cases differences were considered statistically significant when p ≤ 0.05 (*), 
p ≤ 0.01 (**) or p ≤ 0.001 (***). 
Multivariate data analyses was performed to assess the ability of synaptic proteins (when 
combined together) to discriminate controls from the different patient groups using 
orthogonal partial least square analyses (SIMCA, version 13.0; Umetrics AB, Sweden). 
Detailed description of the multivariate statistical analysis can be found in the supplementary 
methods section. We calculated the sensitivity, specificity, positive predictive values and 
negative predictive values of the group separations from the Q2(Y) values obtained in each 
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model. Results from the multivariate analyses were visualized in loadings plots, where the 
synaptic proteins are presented on the x-axis according to their importance for the separation 
of the different groups. Measures below zero have a lower value in patients whereas 
measures above zero have a larger value in patients compared to the control group. 
Covariance is plotted on the y-axis. For every synaptic protein, the Jack-knifed confidence 
intervals are shown. The proteins with a confidence interval that includes zero have low 
classification power.  
 
3. RESULTS 
3.1 Demographical characteristics of the samples 
Key cohort characteristics are shown in Table 1. There were no significant differences in the 
pH or in the post-mortem delay between the groups. AD patients were significantly older 
than all the other three groups but no other group differed significantly in age. Correlations 
between age and MMSE decline scores were observed in PDD in the prefrontal cortex 
(Rho=0.553, p=0.0076, n=22), temporal lobe (Rho=0.369, p=0.0346, n=33) and in the 
inferior parietal lobe (Rho=0.369, p=0.0346, n=33).  
3.2 Differences in the levels of synaptic proteins between diagnostic groups 
Specificity of the antibody pairs employed in the ELISA studies assessed by 
immunoprecipitation in cerebrospinal fluid show that all the 3 pairs of antibodies were highly 
specific for recognizing neurogranin, Rab3A or SNAP25 proteins (Supplementary Figure 1).  
Western blot and ELISA analyses both demonstrated that, both pre-synaptic proteins Rab3A 
and SNAP25 and postsynaptic protein neurogranin had reduced levels across the brain 
regions in the three dementia groups compared to controls (Table 2, Figure 1). We have 
observed an overall 20-51% decrease in the levels of synaptic proteins in DLB patients, 16-
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41% in PDD patients and 22-42% decrease in AD patients compared to non-neurological 
controls throughout all the four studied brain regions. ELISA assay indicated similar changes 
in most brain regions. 
Immunohistochemistry supported the direction of changes seen for neurogranin in most of the 
examined cortical areas with only moderate decrease identified for Rab3A and no overall 
differences found for SNAP25 (Supplementary Figure 2). Figure 1A- 1H illustrates typical 
immunolabeling of presynaptic proteins in the anterior cingulate cortex (BA24) and Figure 
1I- 1L displays typical immunolabeling of neurogranin in the temporal lobe (BA21) in non-
neurological controls versus the various dementia cases. 
3.3 Panel of pre and postsynaptic proteins discriminate between control and dementia 
diagnoses 
The multivariate analyses results showed that synaptic protein levels were able to provide a 
clear separation between controls and the different patient groups. All models were 
statistically significant and showed sensitivity, specificity, positive and negative predictive 
values that were all above 90% in the case of PDD and DLB groups and were close to 90% in 
AD patients (Table 3).  
The first model showed a good predictive power of Q2(Y) = 0.699 in discriminating controls 
from patients with PDD. The variables that contributed to the separation between these 
groups were SNAP25 in BA9 and BA24, Rab3A in BA40 and BA21, neurogranin in BA40, 
BA24 and BA21 (Fig. 2). The second model showed a sound predictive power of Q2(Y) = 
0.719 in discriminating controls from DLB patients. All synaptic proteins significantly 
contributed to the separation between groups, with the exception of Rab3A in BA24 and 
SNAP25 in BA21 (Fig. 2). The third model showed a good predictive power of Q2(Y) = 
0.781 in the discrimination of controls from AD patients. The synaptic proteins that 
significantly contributed to the separation were neurogranin in BA40, BA9 and BA24, 
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SNAP25 in BA9 and BA24, and Rab3A in BA40 and BA9 (Fig. 2). Significant separation 
was not achieved between the three neurodegenerative diseases (data not shown).  
3.4 Associations between synaptic proteins and neuropathological scores 
Significant associations between synaptic protein levels and neuropathological measures are 
summarized in Supplementary Table 3 and significant correlations are plotted in 
Supplementary Figure 3. There were significant correlations between the postsynaptic 
neurogranin levels and tangle scores in the prefrontal cortex of PDD patients (Rho= 0.529, p 
= 0.009, n=23) as well as in the anterior cingulate cortex (Rho= 0.737 p = 0.001, n=16) and 
in the inferior temporal lobe (Rho= 0.529, p = 0.029, n=17) of AD patients. Synaptic vesicle 
protein Rab3A correlated significantly with alpha-synuclein in the inferior parietal lobe both 
in PDD (Rho= 0.439, p = 0.011, n=32) as well as in DLB (Rho=-0.3, p = 0.045, n=45). 
Rab3A presented further positive correlations with plaque scores in the temporal lobe (Rho= 
0.475, p = 0.025, n=22) in PDD. Presynaptic protein SNAP25 presented negative correlations 
with tangle scores in AD in the inferior parietal lobe (Rho= -0.696, p = 0.025, n=10).  
3.5 Correlations between synaptic proteins and cognitive impairment 
Ten out of 44 DLB cases in BA40 and two out of 18 AD cases had no MMSE decline scores 
available (Supplementary Table 1). We observed that the rate of cognitive decline was 
associated with both presynaptic proteins, Rab3A and SNAP25. Inverse correlations to 
MMSE decline were present for Rab3A and SNAP25 levels assessed by ELISA assay in 
patients with DLB and AD respectively (Fig. 3). Reduced Rab3A and SNAP25 levels were 
associated with a more rapid cognitive decline in the inferior parietal lobe in the case of 
Rab3A (Rho=-0.424, p=0.012, n=34) and in prefrontal cortex in the case of SNAP25 (Rho=-
0.502, p=0.047, n=16). In addition, we have performed correlations without a potential 
outlier for SNAP25, and the correlation coefficient barely changes, from -0.502 to -0.499, 
indicating that the observed association is not driven by this potential outlier. In contrast, 
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neurogranin showed an association with higher MMSE scores measured at the last 
assessment prior to death in DLB patients (inferior parietal lobe Rho=-0.388, p = 0.023, 
n=34) (Supplementary Figure 4). No significant associations were found between synaptic 
proteins and cognition in Parkinson`s disease.   
 
4. DISCUSSION 
Our biochemical studies conducted in post-mortem brain tissues have highlighted significant 
loss of pre- and post-synaptic proteins in DLB and PDD. The pre- and postsynaptic proteins 
examined were selected for their roles in crucial synaptic processes such as vesicle docking 
(SNAP25), vesicle recycling (Rab3A) and postsynaptic signalling (neurogranin). Changes in 
these proteins were able to accurately discriminate between age matched controls and 
individuals with PDD and DLB with high sensitivity and specificity (>90%). Synaptic protein 
changes of Rab3A and neurogranin in the inferior parietal lobe (BA40) as well as SNAP25 in 
prefrontal cortex (BA9) provided the best discrimination between the disease groups and non-
neurological controls. These proteins also merit further evaluation as disease biomarkers and 
the related synaptic pathways are highlighted as potentially important treatment targets. 
Prefrontal and cingulate cortex displayed the most robust synaptic protein changes in 
all three dementia groups with decrease in both pre- and postsynaptic protein levels between 
23-43% compared to control non demented cases. The most robust significant changes 
reflecting synaptic dysfunction were observed in DLB patients followed by PDD cases and 
AD patients.  A handful of studies have shown synaptic loss in AD [11, 24-26]. A recent 
study has detected early synaptic dysfunction that preceded amyloid beta pathology in animal 
model for familial AD (APP/PSEN1), where independent of tau pathology, synaptic 
dysfunction was already detectable prior to the early rise of different soluble amyloid beta 
peptides [27]. Synaptic dysfunction has been also shown in Parkinson`s disease [15], whereas 
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much less is known regarding synaptic pathology in DLB. We have recently identified 
reductions of synaptophysin, syntaxin and synaptosome-associated protein in the visual 
association cortex in DLB and an association between zinc transporter 3 and postsynaptic 
density protein 95 and the level of cognitive impairment in DLB have been reported [28]. 
More recently, reductions of synaptophysin as well as syntaxin and synaptosome-associated 
protein of 25 kD (SNAP-25) were identified in the visual association cortex in DLB [29], a 
brain area where pathological changes are usually not pronounced [30], suggesting the 
possibility that these may be early pathological changes. 
More detailed studies, including other brain regions and a larger panel of proteins are needed 
to explore whether there are disease-related differences. The current work adds important 
new information by confirming the discriminatory power of changes in synaptic proteins to 
distinguish between the respective disease groups and controls, and highlights change in 
specific synaptic proteins. 
Recent studies have suggested that early stages of tau accumulation have a toxic 
action on synaptic function [31, 32].  Positive correlations between neurogranin and p-tau and 
total tau in cerebrospinal fluid of patients with AD were reported [33], supporting the notion 
that cerebrospinal fluid concentrations of neurogranin and possibly other synaptic proteins 
are directly or indirectly associated with the level of synaptic degeneration. We found that 
both the postsynaptic protein neurogranin as well as the presynaptic protein SNAP25 were 
positively correlated with tangle scores in different brain regions. Similar positive 
associations between another postsynaptic protein, postsynaptic density protein 95 and 
increasing amyloid beta levels in cortical regions have been reported in Alzheimer’s disease, 
suggesting that certain forms of synaptic process are strongly involved in the regional 
specificity of both tau and amyloid beta levels [34, 35].  
13 
 
We have found a number of associations with the level of Lewy body pathology. 
Specifically, the presynaptic Rab3A protein was associated with tangle scores and alpha-
synuclein scores in the anterior cingulate cortex and the inferior parietal lobe. Interestingly, 
the Rab3A recycling machinery is closely linked to synuclein’s membrane association and 
dissociation cycle known to increase α-synuclein sequestration leading to cognitive 
consequences [36]. Our results presenting associations between Rab3A and synuclein 
pathology are in line with previous findings reporting increased binding of Rab3A to alpha-
synuclein aggregates in DLB [37], proposing that decreased Rab3A levels, is likely to 
directly affect not only the reserve synaptic vesicle pool but alpha-synuclein pathology as 
well. The detailed relationship between synaptic machinery proteins with tau, amyloid beta 
and α-synuclein levels needs to be further explored. It remains possible that some regional 
associations observed in our study might be mediated by other confounding factors but it 
definitely underlines the involvement of the synaptic activity in the various dementias.   
Among the main findings of this study are that decreased Rab3A and SNAP25 levels 
correlated with increased rate of cognitive decline in DLB and AD, respectively. In DLB, the 
region showing such associations for Rab3A was the inferior parietal lobe, which has been 
associated with the typical visuospatial impairment [38, 39]. Associations for SNAP25 and 
cognition in AD were limited to the prefrontal cortex. Prefrontal cortex is known to be 
involved in executive functions and cognition [40], the deterioration of which is encountered 
early in the development of Lewy body dementias while it is affected only in later stages of 
AD. The apparent contradiction in the involvement of the synaptic pathology and cognitive 
association of the affected regions, i.e. parietal lobe in dementia with Lewy body and 
prefrontal cortex in AD, may represent the implication of different clinical features but also 
underlines the importance of the disease stage of the sample available for post-mortem 
studies since we have seen cognitive correlations of synaptic proteins in regions that are 
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involved late in the course of the diseases. As post-mortem brain studies usually have limited 
number of early stage pathology, cerebrospinal fluid or serum samples of early dementia 
patients could add another level to our current knowledge and progression of these dementias. 
Our current data suggest that stabilization of Rab3A levels may represent an important 
treatment strategy in DLB patients, while SNAP25 could be a new marker in the progression 
of AD.  
One of the strengths of our study is that we have combined multiple techniques to 
measure synaptic changes in brain tissues which generally point towards the same 
conclusions namely the loss of presynaptic and postsynaptic proteins throughout the studied 
brain regions. Another advantage of our study is the relatively large number of cases with 
DLB and PDD, giving us more potential to mitigate the influence of the individual changes 
that occur in smaller cohorts. One limitation of our study is that our AD cohort was 
comprised of only 18 cases, however our results are in agreement with previous findings 
regarding SNAP25 as a promising biomarker for synapse degeneration in AD[41]. The 
availability of longitudinal standardized clinical data in brain bank studies is a relatively 
unique feature of our study though longitudinal MMSE scores were not available for all 
patients (Supplementary Table 1). Finally, the prospective design with standardized cognitive 
assessments is a unique strength of the study.  
4.1 Conclusions and future implications 
Loss of synapses is an early and robust correlate of cognitive decline in Alzheimer’s disease 
[11, 25], and accumulating evidence point in the direction of the importance of synaptic 
changes in other dementias as well, including DLB and PDD [8, 28, 42]. Our work strongly 
supports this as an exciting area, with potential to improve diagnosis and identify novel 
therapeutic targets. Cortical reductions of three pre- and post-synaptic proteins discriminated 
Lewy body dementia and AD from non-neurological controls with high sensitivity and 
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specificity. In addition, we report evidence that decreased levels of presynaptic vesicle 
protein Rab3A and SNAP25 are associated with cognitive impairment and neuropathological 
scores in DLB and AD.  
Our findings suggest that the proposition that synaptic markers can predict cognitive decline 
in AD [33], should be extended to Lewy body diseases. Finally, the relationship of Rab3A 
and SNAP25 to disease pathology and impact on cognitive decline highlights their 
importance as a treatment target and its potential as a future biomarker of disease progression 
for clinical trials is a path that should be further explored. 
 
 
RESEARCH IN CONTEXT 
Systematic review: A significant decrease in cortical synapses has been previously reported 
in AD. Initial work suggests that the loss of synapses is more robustly correlated with 
cognitive decline than with traditional markers of AD pathology, suggesting that these 
changes are already evident at the earliest stages of disease.  
Interpretation: Decreased Rab3A and SNAP25 levels correlated with increased rate of 
cognitive decline in DLB and AD and neuropathological markers suggesting that stabilization 
of synaptic protein levels such as Rab3A may represent an important treatment strategy in 
DLB patients, while SNAP25 could be a new marker in the progression of AD. 
Future directions: The role of synaptic proteins as possible predictors of cognitive decline in 
AD and DLB needs to be evaluated by further biomarker studies in CSF samples.  
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FIGURE LEGENDS AND TABLES 
Figure 1. Changes in synaptic protein levels assessed by Western blotting and immunolabelling. 
Rab3A (A- D) and SNAP25 (E- H) immunostaining was performed in BA24, while neurogranin 
staining (I- L) was performed in BA21. Compared to non-neurological controls (A and I) both Rab3A 
and neurogranin immunolabelling revealed mild to moderate decreased levels of synaptic proteins in 
PDD (B and J) and DLB (C and K), while no changes were observed in AD cases. SNAP25 showed 
similar levels of immunoreactivity in non-neurological controls (E) and the dementia cases studied (F- 
H). Scale bars represent 25 microns. Neurogranin, Rab3A and SNAP25 levels present changes in 
prefrontal cortex (BA9) assessed by semiquantitative western blotting (Panel M and N). Statistical 
analyses were performed using Kruskal-Wallis test followed by post hoc Dunn`s multiple comparison 
test. Neurogranin levels both in PDD, DLB and AD were significantly reduced when compared to 
non-neurological controls. Similarly, Rab3A levels were significantly reduced in all three dementia 
diagnoses when compared to controls. SNAP25 levels were also found to be decreased in PDD and 
DLB while they were found to have comparable levels in AD and control non-neurological cases. The 
bars represent the mean values with inter-quartile range. Abbreviations used C=control, 
NRGN=neurogranin. For all figures * p<0.05, **p<0.01, ***p<0.001  
 
Figure 2. Multivariate analyses results showing the contribution of synaptic proteins to 
discriminate controls from the different patient groups. Plots showing the variables of importance 
and their corresponding jack-knifed confidence intervals for the separation between controls and PDD 
patients (A), controls and DLB patients (B), controls and AD patients (C). A measure with high 
covariance is more likely to have an impact on group separation than a variable with low covariance. 
Measures with confidence intervals that include zero have low reliability. 
 
Figure 3. Correlations between presynaptic proteins and cognitive decline. SNAP25 and Rab3A 
protein levels assessed by ELISA analyses present negative correlations with cognitive impairment 
assessed by yearly MMSE decline scores in prefrontal cortex (BA9) and inferior parietal lobe (BA40) 
of AD patients and DLB patients respectively, analysed by nonparametric Spearman correlations.  
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Table 1. Demographic characteristics of the subjects used in this study according to clinical diagnosis. 
 
Diagnosis 
Gender 
(M/F) % 
Age at death PMD  (h) pH MMSE at 
death 
MMSE 
decline 
Coded 
Braak 
staging 
Control (25) 60/40 79.8  ± 1.5 39.1  ± 4.6 6.47  ± 0.05 n/a n/a 1 (0-2) 
PDD (34) 53/47 79.9  ± 1.0 33.5  ± 2.7 6.44  ± 0.06 12.7 (0-27) 2.1 + 0.3 1 (0-2) 
DLB (52) 60/40 81.3  ± 0.9 41.5  ± 3.9 6.37  ± 0.06 13.9 (0-30) 3.0 + 0.4 3 (1-3) 
AD (18) 33/67 88.1  ± 1.7  35  ± 5.3 6.30  ± 0.08 8.5 (0-19) 3.5 + 0.9 3 (2-3) 
Values are expressed with standard error of the mean, coded Braak stage is presented as the mean with the range 
in brackets. Coded Braak stages represent neurofibrillary Braak staging 0=0; 1= stages 1/ 2; 2=stages 3/ 4 and 
3=stages 5/ 6. Abbreviations used: PMD=post mortem delay, MMSE= mini mental state examination. 
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Table 2. Differences in the synaptic proteins neurogranin, Rab3A and SNAP25 assessed by Western 
blotting and ELISA.  
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  NRGN BA9 NRGN BA21 NRGN BA24 NRGN BA40 
PDD 38% p<.01 30% p<.05 36%   45% p<.001 
DLB 40% p<.01 51% p<.001 35% p<.01 46% p<.001 
AD 35% p<.05 NA   24%   28%   
  Rab3A BA9 Rab3A BA21 Rab3A BA24 Rab3A BA40 
PDD 30% p<.01 16%   43% p<.05 24%   
DLB 41% p<.01 27% p<.05 39% p<.01 42% p<.001 
AD 42% p<.01 NA   38% p<.01 22%   
  SNAP25 BA9 SNAP25 BA21 SNAP25 BA24 SNAP25 BA40 
PDD 37% p<.05 26% p<.05 35% p<.05 33% p<.001 
DLB 42% p<.01 24% p<.05 41% p<.001 20%   
AD 23%   NA   33% p<.05 34% p<.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EL
IS
A
 
  NRGN BA9 NRGN BA21 NRGN BA24 NRGN BA40 
C 185.4 (83.1)   132.9 (34.8)   158.1 (35)   201.8 (41.2)   
PDD 114.2 (56.1) 
(38%) 
p<.05 115.1 (40) 
(13%) 
  123 (13) 
(22%) 
p<.05 130.6 (27.9) 
(35%) 
p<.001 
DLB 142.4 (78.4) 
(23%) 
  91.3 (22.3) 
(31%) 
p<.001 124.5 (30) 
(21%) 
p<.01 125.9 (34.4) 
(38%) 
p<.001 
AD 95.2 (49.6) 
(49%) 
p<.001 NA   141.6 (23.1) 
(10%) 
  117.7 (17) 
(42%) 
p<.001 
  Rab3A BA9 Rab3A BA21 Rab3A BA24 Rab3A BA40 
C 180.6 (40.9)   152.4 (56.3)   112.6 (28.6)   157.3 (26.9)   
PDD 150.3 (33.3) 
(17%) 
  128.8 (39.3) 
(15%) 
  113 (20.1) 
(0%) 
  103.2 (17.4) 
(34%) 
p<.001 
DLB 138 (31.3) 
(24%) 
p<.05 104 (29.3) 
(32%) 
p<.001 106.8 (24.8) 
(5%) 
  115 (15.7) 
(27%) 
p<.001 
AD 132.7 (25.3) 
(27%) 
p<.01 NA   99.95 (18.78) 
(11%) 
  113.2 (14.6) 
(28%) 
p<.001 
  SNAP25 BA9 SNAP25 BA21 SNAP25 BA24 SNAP25 BA40 
C 178.7 (35.7)   98.9 (29.5)   158.8 (35.7)   142.3 (30.8)   
PDD 95.3 (27.6) 
(47%) 
p<.001 85.2 (18.9) 
(14%) 
  135.1 (24) 
(15%) 
p<.05 84.9 (37.4) 
(40%) 
p<.05 
DLB 92.1 (24) 
(48%) 
p<.001 90.9 (20) 
(8%) 
  129.2 (33.2) 
(19%) 
p<.05 75.5 (43.9) 
(47%) 
p<.01 
AD 107.3 (32.1) 
(40%) 
p<.001 NA   126.7 (28.5) 
(20%) 
p<.05 85.75 (25.5) 
(40%) 
p<.01 
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Differences in protein levels between disease groups and controls were determined using Kruskal-Wallis test 
followed by Dunn`s post hoc test. Western blot changes are expressed as percentage compared to control, while 
ELISA values are expressed in pg/mL (means ± standard deviation) as well as in percentage changes compared 
to control in parenthesis. Abbreviations used: NRGN = neurogranin. p values represent statistical differences 
resulting from comparisons of dementia cases to non-demented control groups. 
 
 
 
 
 
 
Table 3. Sensitivity, specificity, positive and negative predictive values for each model. 
Abbreviations used: C= Control CI= confidence interval; PPV= positive predictive value; NPV= negative 
predictive value. 
Models Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
PPV (95% CI) NPV (95% CI) 
PDD vs C  97.1 (85.1-99.5) 100 (80.6-100) 100 (89.3-100) 94.1 (71.2-99.0) 
DLB vs C 94.7 (82.7-98.5) 93.8 (71.7-98-9) 97.3 (85.8-99.6) 100 (78.0-100) 
AD vs C 82.4 (59.0-93.8) 90.5 (77.3-99.2) 87.5 (61.6-98.1) 86.3 (65.1-96.9) 
PDD vs DLB 56.8 (40.9-71.3) 63.6 (46.6-77.8) 63.6 (45.1-79.6) 56.8 (39.5-72.9) 
PDD vs AD 43.8 (19.8-70.1) 81.8 (64.5-93.0) 53.9 (25.1-80.8) 75.0 (57.8-87.9) 
DLB vs AD 43.8 (19.8-70.1) 81.1 (64.8-92.0) 50.0 (23.0-77.0) 76.9 (60.7-88.9) 
